Modulators of toll-like receptors

US11110091B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11110091-B2
Application numberUS-201816201221-A
CountryUS
Kind codeB2
Filing dateNov 27, 2018
Priority dateDec 9, 2008
Publication dateSep 7, 2021
Grant dateSep 7, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

First claim

Opening claim text (preview).

We claim: 1. A compound of Formula II: or a pharmaceutically acceptable salt thereof, wherein: Y—Z is —CR 4 R 5 —CR 4 R 5 ; L 1 is —NH— or —O—; R 1 is C 1 -C 6 alkyl C 3 -C 12 saturated carbocyclyl, C 4 -C 20 saturated carbocyclylalkyl, or C 6 -C 20 arylalkyl; X 1 is —CH 2 ; D is phenyl substituted with -L 2 -NR 6 R 7 ; each L 2 is independently C 1 -C 6 alkylene; each R 3 is independently halogen, cyano, or C 1 -C 6 haloalkyl; n is 0 or 1; R 4 and R 5 are each H; R 6 and R 7 are each independently H, C 1 -C 6 alkyl, or C 4 -C 20 saturated carbocyclylalkyl, —C(O)R 8 , —S(O)R 8 , —S(O) 2 R 8 , or —C(O)OR 8 ; or R 6 and R 7 , taken together with the nitrogen to which they are both attached, form a 4-6 membered saturated heterocycle comprising 0 to 2 heteroatoms selected from N, O, or S; and R 8 is H or C 1 -C 6 alkyl. 2. The compound of claim 1 selected from the group consisting of or a pharmaceutically acceptable salt thereof. 3. A compound of formula: or a pharmaceutically acceptable salt thereof.

Assignees

Inventors

Classifications

  • Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

  • Drugs for disorders of the respiratory system · CPC title

  • for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

  • Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols · CPC title

  • Interferons {[IFN]} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11110091B2 cover?
Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
Who is the assignee on this patent?
Gilead Sciences Inc
What technology area does this patent fall under?
Primary CPC classification C07D475/06. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).